Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
- None.
- None.
The collaboration between Haystack Oncology and TriSalus Life Sciences represents a significant stride in the enhancement of therapeutic strategies for challenging cancers such as hepatocellular carcinoma, intrahepatic cholangiocarcinoma and pancreatic adenocarcinoma. The utilization of Haystack MRD technology to detect circulating tumor DNA (ctDNA) with high sensitivity is crucial. It allows for the monitoring of molecular responses to SD-101, potentially improving early detection of treatment efficacy which is a pivotal aspect of patient management and could lead to more personalized treatment protocols.
From an oncological perspective, the ability to measure ctDNA effectively can transform the current landscape of cancer treatment by providing a more accurate, non-invasive biomarker for tumor burden. This could result in earlier therapeutic interventions and might also facilitate the development of adaptive clinical trials that can be modified in real-time based on ctDNA levels, potentially leading to more rapid approval of effective treatments.
TriSalus' SD-101, a class C toll-like receptor-9 (TLR9) agonist, represents an innovative approach in the realm of immunotherapies, which are increasingly becoming pivotal in cancer treatment. The research collaboration with Haystack Oncology could enhance the drug's clinical development by providing molecular insights that are not readily available through conventional imaging techniques. The ability to overcome intratumoral pressure via Pressure-Enabled Drug Delivery™ (PEDD™) is particularly noteworthy, as it addresses a common barrier to effective drug delivery in solid tumors.
The partnership could potentially accelerate the clinical trial process, leading to faster drug development timelines and earlier availability of new therapies to patients, which is of paramount importance for those suffering from aggressive cancers with limited treatment options. This collaboration could also set a precedent for future oncology drug development, emphasizing the importance of molecular diagnostics in conjunction with therapeutic advancements.
The strategic alliance between Haystack Oncology and TriSalus Life Sciences could have substantial implications for the stakeholders of both entities. For Quest Diagnostics, the parent company of Haystack Oncology, this collaboration may enhance the company's reputation in the precision medicine space, potentially leading to an increase in its market share in oncology diagnostics. This, in turn, could positively influence investor sentiment and the company's stock performance.
On the other hand, for TriSalus Life Sciences, the use of Haystack's MRD technology could provide a competitive edge in the clinical development of SD-101. If the trials demonstrate significant efficacy, it could lead to an increase in the company's valuation and attract further investment. It is important to monitor the outcomes of the phase 1 and 1b clinical trials, as positive results could lead to a surge in stock prices for both companies, whereas any setbacks might have an adverse effect.
"Haystack MRD is specifically designed and developed to accurately detect circulating tumor DNA (ctDNA) with unparalleled sensitivity in patients with low tumor burden and in clinically challenging cancer types," said Dan Edelstein, Vice President and General Manager, Haystack Oncology. "Haystack MRD's sensitivity enables clinical investigators to closely follow molecular response and measure early evidence of treatment efficacy. We're excited to collaborate with TriSalus to support the clinical development of SD-101 in combination with their unique therapy delivery technology, which aims to overcome challenges associated with treating liver and pancreatic tumors."
Hepatocellular carcinoma is the most common form of liver cancer. Intrahepatic cholangiocarcinoma is cancer that occurs in the parts of the bile ducts that are within the liver. Pancreatic adenocarcinoma is the most common form of pancreatic cancer.
"A significant challenge in the development of immunotherapies for liver and pancreatic tumors is early measurement of response to treatment. Conventional imaging response assessment methods may be misleading in certain situations, and accurate ctDNA assays offer the potential to identify meaningful biologic activity in difficult to treat cancers," says Steven Katz, MD, Chief Medical Officer of TriSalus Life Sciences. "We are thrilled to work with Haystack in pursuit of our mission to develop better therapeutic options for patients with liver and pancreatic tumors."
About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD™, a next generation tumor informed approach for the measurement of minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million. Haystack Oncology works with biopharmaceutical companies to accelerate and improve efficiency of clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD (Research Use Only) is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in
About TriSalus
TriSalus is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with cancer. TriSalus' proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its highly effective drug delivery technology with immunotherapeutics.
View original content to download multimedia:https://www.prnewswire.com/news-releases/haystack-oncology-developer-of-haystack-mrd-and-trisalus-life-sciences-collaborate-in-connection-with-the-clinical-development-of-trisalus-tlr9-agonist-in-hepatocellular-carcinoma-intrahepatic-cholangiocarcinoma-and-pancreat-302039834.html
SOURCE Quest Diagnostics
FAQ
What is the research collaboration between Haystack Oncology and TriSalus Life Sciences about?
What is the purpose of utilizing Haystack MRD™ technology in the collaboration?
What is the focus of the partnership between Haystack Oncology and TriSalus Life Sciences?
How does the collaboration aim to address challenges in the development of immunotherapies for liver and pancreatic tumors?
